Physician profile
Elsa Gutierrez
NPI 1366438061
$7,271.87
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,577 · 2020: $25.38 · 2021: $308 · 2022: $320 · 2023: $484 · 2024: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033 · Education: $9.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.34 |
| Education | $9.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $4,185.20 | 2019-2023 | Sotyktu |
| Dermavant Sciences, INC. | $465.69 | 2023-2024 | Vtama |
| Pfizer INC. | $435.28 | 2019-2023 | |
| Abbvie INC. | $374.38 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $356.97 | 2019-2021 | |
| Celgene Corporation | $274.27 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $229.80 | 2019-2020 | |
| Galderma Laboratories, L.P. | $210.91 | 2019 | |
| Aclaris Therapeutics, INC. | $195.21 | 2019 | |
| Amgen INC. | $178.39 | 2024 | Otezla |
| Genentech USA, INC. | $125.00 | 2021 | |
| Lilly USA, LLC | $89.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $56.78 | 2019 | |
| Prugen, INC. Pharmaceuticals | $40.78 | 2019 | |
| Mayne Pharma Commercial LLC | $22.28 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $17.75 | 2019 | |
| Leo Pharma INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elsa Gutierrez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.